Biofil Chemicals & Pharmaceuticals cash flow

·Pharma & HealthChart ›
Latest FY26
Cash from operations
−₹0.6cr−₹1.9 cr in FY25
Capital spending
₹0.2cr+100.3% on FY25
Free cash flow
−₹0.8cr−₹2.0 cr in FY25
Cash from financing
₹2.5cr−₹0.0 cr in FY25
₹ crore except per share
Tap a line for its trendLast 12Mto Jun 2026FY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
Adjustments to reconcile profit — non-cash items
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
—0.30.40.40.4
—0.00.00.00.0
—−0.00.00.2−0.1
Changes in working capital
—−0.7−0.8−1.30.1
—10.7−5.3−12.5−13.3
—−0.3−0.10.10.1
—0.0−0.00.00.0
—−13.93.414.912.1
—0.0−0.10.00.2
—0.00.0−0.00.0
—0.5−0.1−0.0−0.1
Cash from operating activities
0.83.40.70.90.8
—−3.4−2.51.7−0.7
—0.1−1.72.50.1
—0.00.00.1−0.0
—0.70.20.20.2
—−0.6−1.92.4−0.1
Cash from investing activities
—0.20.10.00.0
—1.30.00.00.0
—1.1−0.1−0.0−0.0
Cash from financing activities
—2.50.00.00.1
—0.00.00.10.0
—0.00.00.00.0
—2.5−0.0−0.10.0
—3.1−2.02.2−0.1
—3.1−2.02.2−0.1
———2.30.0
Reference items
0.80.60.80.81.2
2.3%2.3%2.5%2.0%3.9%
−0.8−0.8−2.02.4−0.1
—1.7−2.02.2—
−₹0.49−₹0.49−₹1.24₹1.46−₹0.08
—−0.22×−3.45×3.37×−0.20×
—0.70.20.20.2
—0.00.00.00.0
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

BIOFILCHEM₹29.26

Biofil Chemicals & Pharmaceuticals Limited

· Pharma & Health
₹ CrorePeersMANGALAMVINEETLABLASAORTINGLOBEKREBSBIOALPABALPHARMANATCAPSUQMcap ₹47.6 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation0.40.40.40.3—
+ Finance Costs0.00.00.00.0—
+ Other Non-cash Items-0.10.20.0-0.0—
Changes in Working Capital
+ Inventories0.1-1.3-0.8-0.7—
+ Trade Receivables — Current-13.3-12.5-5.310.7—
+ Other Current Assets0.10.1-0.1-0.3—
+ Other Non-current Assets0.00.0-0.00.0—
+ Trade Payables — Current12.114.93.4-13.9—
+ Other Financial Liabilities — Current0.20.0-0.10.0—
+ Other Financial Liabilities — Non-current0.0-0.00.00.0—
+ Other Current Liabilities-0.1-0.0-0.10.5—
Cash from Operating Activities
Profit Before Tax (per I/S)0.80.90.73.40.8
+ Total Adjustments (incl. Working Capital)-0.71.7-2.5-3.4—
Cash from Operations (pre-tax)0.12.5-1.70.1—
+ Other Inflows / (Outflows) — Operating-0.00.10.00.0—
+ Income Taxes Paid0.20.20.20.7—
Cash from Operating Activities-0.12.4-1.9-0.6—
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)0.00.00.10.2—
+ Disp of Fixed Assets0.00.00.01.3—
Cash from Investing Activities-0.0-0.0-0.11.1—
Cash from Financing Activities
+ Proceeds from Borrowings0.10.00.02.5—
+ Repayment of Borrowings0.00.10.00.0—
+ Interest Paid0.00.00.00.0—
Cash from Financing Activities0.0-0.1-0.02.5—
Net Changes in Cash (pre-FX)-0.12.2-2.03.1—
Net Changes in Cash-0.12.2-2.03.1—
Closing Cash0.02.3———
Reference Items
EBITDA1.20.80.80.60.8
EBITDA Margin %3.892.042.542.292.29
Free Cash Flow (CFO − Capex)-0.12.4-2.0-0.8-0.8
Free Cash Flow to Equity—2.2-2.01.7—
Free Cash Flow per Basic Share-0.081.46-1.24-0.49-0.49
Cash Flow to Net Income-0.203.37-3.45-0.22—
Cash Paid for Taxes0.20.20.20.7—
Cash Paid for Interest0.00.00.00.0—
As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.